HALO
Halozyme Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$8.24B
P/E Ratio
24.39
EPS
$2.85
Beta
0.87
52W High
$82.22
52W Low
$51.06
50-Day MA
$67.43
200-Day MA
$69.24
Dividend Yield
—
Profit Margin
23.10%
Forward P/E
9.62
PEG Ratio
-2.50
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $1.51B |
| Gross Profit (TTM) | $1.16B |
| EBITDA | $953.01M |
| Operating Margin | 49.00% |
| Return on Equity | 99.40% |
| Return on Assets | 22.10% |
| Revenue/Share (TTM) | $12.72 |
| Book Value | $1.85 |
| Price-to-Book | 37.54 |
| Price-to-Sales (TTM) | 5.46 |
| EV/Revenue | 6.68 |
| EV/EBITDA | 16.14 |
| Quarterly Earnings Growth (YoY) | 31.20% |
| Quarterly Revenue Growth (YoY) | 42.20% |
| Shares Outstanding | $118.61M |
| Float | $117.25M |
| % Insiders | 1.06% |
| % Institutions | 107.62% |
Historical Volatility
HV 10-Day
38.27%
HV 20-Day
31.50%
HV 30-Day
35.18%
HV 60-Day
31.98%
HV Rank
81.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($83.90 target)
2
Strong Buy4
Buy3
Hold1
SellMore HEALTHCARE Stocks
Data last updated: 6/13/2026